Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.
Patients with advanced cancers that failed to current available therapies;
Life expectancy >12 weeks;
Adequate heart, lung, liver, kidney functions;
Available for tumor biopsy or cancerous effusions;
Had accepted gene therapy before;
Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity;
Active infectious disease related to bacteria, virus, fungi, et al;
Other severe diseases that the investigators consider not appropriate;
Second Affiliated Hospital of Guangzhou Medical University
Lead sponsor
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
Collaborator